US 11,945,794 B2
Nuclear transport modulators and uses thereof
Erkan Baloglu, Stoneham, MA (US); Sharon Shacham, Newton, MA (US); Dilara McCauley, Arlington, MA (US); Trinayan Kashyap, Framingham, MA (US); William Senapedis, Millis, MA (US); Yosef Landesman, Brookline, MA (US); Gali Golan, Mesilat Zion (IL); Ori Kalid, Pardes Hanna (IL); and Sharon Shechter, Andover, MA (US)
Assigned to Karyopharm Therapeutics Inc., Newton, MA (US)
Filed by Karyopharm Therapeutics Inc., Newton, MA (US)
Filed on Aug. 23, 2021, as Appl. No. 17/409,150.
Application 17/409,150 is a continuation of application No. 16/519,955, filed on Jul. 23, 2019, granted, now 11,124,493.
Application 16/519,955 is a continuation of application No. 15/651,856, filed on Jul. 17, 2017, granted, now 10,407,405, issued on Sep. 10, 2019.
Application 15/651,856 is a continuation of application No. 14/900,469, granted, now 9,738,624, issued on Aug. 22, 2017, previously published as PCT/US2014/043479, filed on Jun. 20, 2014.
Claims priority of provisional application 61/838,172, filed on Jun. 21, 2013.
Prior Publication US 2022/0177445 A1, Jun. 9, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 249/08 (2006.01); A61K 31/4196 (2006.01); A61K 31/422 (2006.01); A61K 31/426 (2006.01); A61K 31/4439 (2006.01); A61K 31/4709 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61P 3/04 (2006.01); A61P 11/00 (2006.01); A61P 17/02 (2006.01); A61P 25/00 (2006.01); A61P 25/28 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); C07D 401/06 (2006.01); C07D 403/06 (2006.01); C07D 405/06 (2006.01); C07D 413/06 (2006.01); C07D 417/06 (2006.01)
CPC C07D 401/06 (2013.01) [C07D 249/08 (2013.01); C07D 403/06 (2013.01); C07D 405/06 (2013.01); C07D 413/06 (2013.01); C07D 417/06 (2013.01)] 18 Claims
 
1. A compound, represented by structural formula IV:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R2 is selected from optionally substituted heteroaryl and optionally substituted aryl.